Early initiation of inhaled corticosteroids does not decrease acute chest syndrome morbidity in pediatric patients...

Area of Science:

• Hematology
• Pulmonology
• Pediatrics

Background:

• Acute chest syndrome (ACS) is a primary cause of mortality in sickle cell disease (SCD).
• Systemic corticosteroids are effective for ACS but increase readmission risk for vaso-occlusive crises (VOC).
• The safety and efficacy of inhaled corticosteroids (ICS) for ACS remain unestablished.

Purpose of the Study:

• To evaluate the efficacy of inhaled corticosteroids (ICS) as a potentially safer alternative to systemic corticosteroids for managing ACS in SCD patients.
• To compare clinical outcomes between SCD patients with ACS who received ICS versus those who did not.

Main Methods:

• Observational, historic cohort study design.
• Comparison of 120 SCD patients with ACS: 65 receiving ICS and 55 not receiving ICS.
• Outcome measures included transfusion rates, oxygen needs, BiPAP, PICU transfer, intubation, readmission, cost, and length of stay.

Main Results:

• No significant differences were observed in transfusion rates, oxygen requirements, BiPAP initiation, PICU transfer, intubation, hospital costs, length of stay, or readmission rates between ICS and non-ICS groups.
• While the non-ICS group had more bilateral infiltrates, the ICS group had more BiPAP initiations.
• Regression analysis and subgroup analysis (with/without asthma) showed no significant outcome differences.

Conclusions:

• Inhaled corticosteroids (ICS) did not demonstrate a significant reduction in ACS morbidity in this observational cohort.
• Further prospective studies are warranted to investigate the role of ICS in managing ACS in SCD.
• The findings suggest ICS may not offer a significant benefit over standard care for reducing ACS complications in SCD.